Home/Pipeline/Undisclosed Colorectal Program(s)

Undisclosed Colorectal Program(s)

Colorectal Cancer

Phase 2Active

Key Facts

Indication

Colorectal Cancer

Phase

Phase 2

Status

Active

Company

Tavanta Therapeutics

About Tavanta Therapeutics

Tavanta Therapeutics is a private, clinical-stage biopharmaceutical company founded in 2019 and headquartered in Cambridge, Massachusetts, with a corporate office in King of Prussia, PA. The company is developing a pipeline of specialty small molecule drugs, primarily targeting colorectal cancer and uro-oncology, with a strategy centered on advancing late-stage assets. Led by an experienced management team with deep expertise in drug development and commercialization, Tavanta is positioned as a pre-revenue entity aiming to bring clinically meaningful therapies to market where treatment options are limited.

View full company profile

Therapeutic Areas

Oncology Colorectal Cancer Uro-oncology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active